Literature DB >> 30952822

Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.

Xiaoyan Feng1, Ling Li1, Jingjing Wu1, Lei Zhang1, Zhenchang Sun1, Xin Li1, Xinhua Wang1, Hui Yu1, Yu Chang1, Xiaolong Wu1, Zhiyuan Zhou1, Guannan Wang2, Wencai Li2, Zhaoming Li1, Xudong Zhang1, Mingzhi Zhang3.   

Abstract

BACKGROUND: T-lymphoblastic lymphoma (T-LBL) is a highly aggressive neoplasm of lymphoblasts of T-cell origin. Although promising improvements have been recently achieved, one third of patients experience relapse or refractory T-LBL. Therefore, optimal strategies for identifying high-risk patients are urgently needed.
MATERIALS AND METHODS: In the present study, 75 newly diagnosed adult patients (aged ≥15 years) with T-LBL were identified and the predictive value of complete blood count (CBC) abnormalities, including lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) on clinical outcomes, was analyzed.
RESULTS: Using the receiver operating characteristic curve to determine the best cutoff values based on survival, it was found that patients with T-LBL with LMR ≤2.8, NLR ≥3.3, and PLR ≥200 had both inferior progression-free survival (PFS) and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0-2 subgroup. In the multivariable analysis, NLR ≥3.3 together with age >40 years and central nervous system (CNS) involvement were identified to be independently associated with shortened PFS, whereas PLR ≥200 and CNS involvement were identified to be independent risk factors for OS. LMR, NLR, and PLR were integrated to generate a "CBC score" model, which well separated adult patients with T-LBL into three risk groups, and the 3-year OS was 84%, 53%, and 30% for low-, intermediate-, and high-risk patients, respectively.
CONCLUSION: Overall, a "CBC score" model was initially promoted for stratification in adult patients with T-LBL using simple, widely available, and easy to interpret parameters in the largest adult T-LBL cohort to date. IMPLICATIONS FOR PRACTICE: Optimal strategies for identifying high-risk patients with T-lymphoblastic lymphoma (T-LBL) are urgently needed. In the largest adult T-LBL cohort to date, simple, inexpensive, widely available parameters were applied and revealed that patients with lymphocyte-monocyte ratio (LMR) ≤2.8, neutrophil-lymphocyte ratio (NLR) ≥3.3, and platelet-lymphocyte ratio (PLR) ≥200 had both inferior progression-free survival and inferior overall survival (OS), in which the differences were much more remarkable in the international prognostic index score 0-2 subgroup. LMR, NLR, and PLR were integrated to generate a "complete blood count score" model, in which the 3-year OS was 84%, 53%, and 30% for low-, intermediate-, and high-risk patients, respectively. © AlphaMed Press 2019.

Entities:  

Keywords:  Complete blood count; Host immunity; Prognosis; Tumor microenvironment; T‐lymphoblastic lymphoma

Mesh:

Substances:

Year:  2019        PMID: 30952822      PMCID: PMC6853117          DOI: 10.1634/theoncologist.2018-0789

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  33 in total

1.  The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.

Authors:  Brady E Beltran; Christian Aguilar; Pilar Quiñones; Domingo Morales; Julio C Chavez; Eduardo M Sotomayor; Jorge J Castillo
Journal:  Leuk Lymphoma       Date:  2015-06-19

Review 2.  Lymphoblastic lymphoma.

Authors:  Sergio Cortelazzo; Andrés Ferreri; Dieter Hoelzer; Maurilio Ponzoni
Journal:  Crit Rev Oncol Hematol       Date:  2017-03-18       Impact factor: 6.312

3.  Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Authors:  Alessandra Romano; Nunziatina Laura Parrinello; Calogero Vetro; Annalisa Chiarenza; Claudio Cerchione; Massimo Ippolito; Giuseppe Alberto Palumbo; Francesco Di Raimondo
Journal:  Ann Hematol       Date:  2018-02-14       Impact factor: 3.673

4.  Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer; Nicola Gökbuget; Werner Digel; Thomas Faak; Michael Kneba; Regina Reutzel; Joanna Romejko-Jarosinska; Jacek Zwolinski; Jan Walewski
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  How I treat T-cell acute lymphoblastic leukemia in adults.

Authors:  Mark R Litzow; Adolfo A Ferrando
Journal:  Blood       Date:  2015-05-12       Impact factor: 22.113

6.  Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Francis J Giles; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Miloslav Beran; Sherry Pierce; Chul S Ha; Fernando Cabanillas; Michael J Keating; Hagop Kantarjian
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

Review 7.  The pro-inflammatory role of platelets in cancer.

Authors:  A K Olsson; J Cedervall
Journal:  Platelets       Date:  2018-03-27       Impact factor: 3.862

Review 8.  The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis.

Authors:  Wei Liang; Napoleone Ferrara
Journal:  Cancer Immunol Res       Date:  2016-02       Impact factor: 11.151

Review 9.  Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: an updated systematic review and meta-analysis of 24 studies.

Authors:  Nan Chen; Wanling Li; Kexin Huang; Wenhao Yang; Lin Huang; Tianxin Cong; Qingfang Li; Meng Qiu
Journal:  Oncotarget       Date:  2017-05-09

10.  Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma.

Authors:  Lihui Shi; Xiaoqi Qin; Huijun Wang; Yonghui Xia; Yuanyuan Li; Xuejing Chen; Lei Shang; Yu-Tzu Tai; Xiaoyan Feng; Prakrati Acharya; Chirag Acharya; Yan Xu; Shuhui Deng; Mu Hao; Dehui Zou; Yaozhong Zhao; Kun Ru; Lugui Qiu; Gang An
Journal:  Oncotarget       Date:  2017-03-21
View more
  6 in total

Review 1.  The Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios as New Prognostic Factors in Hematological Malignancies - A Narrative Review.

Authors:  Paulina Stefaniuk; Agnieszka Szymczyk; Monika Podhorecka
Journal:  Cancer Manag Res       Date:  2020-04-29       Impact factor: 3.989

2.  Utility of inflammatory markers to predict adverse outcome in acute pancreatitis: A retrospective study in a single academic center.

Authors:  Mohamad Mubder; Banreet Dhindsa; Danny Nguyen; Syed Saghir; Chad Cross; Ranjit Makar; Gordon Ohning
Journal:  Saudi J Gastroenterol       Date:  2020-07-21       Impact factor: 2.485

3.  Complete Blood Count Score Model Predicts Inferior Prognosis in Primary Central Nervous System Lymphoma.

Authors:  Yuhua Feng; Yiping Liu; Meizuo Zhong; Leyuan Wang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

4.  A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children.

Authors:  Leyuan Wang; Lin Yuan; Xizi Du; Kai Zhou; Yu Yang; Qingwu Qin; Liangchun Yang; Yang Xiang; Xiangping Qu; Huijun Liu; Xiaoqun Qin; Chi Liu
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

5.  Distribution of Peripheral Blood Cells in Esophageal Cancer Patients During Concurrent Chemoradiotherapy Predicts Long-Term Locoregional Progression Hazard After Treatment (GASTO1072).

Authors:  Liangyu Xu; Jianzhou Chen; Hong Guo; Ruihong Huang; Longjia Guo; Yuanxiang Yu; Tiantian Zhai; Fangcai Wu; Zhijian Chen; Derui Li; Chuangzhen Chen
Journal:  Cancer Manag Res       Date:  2021-05-25       Impact factor: 3.989

6.  CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.

Authors:  Yue Song; Wei Song; Zhaoming Li; Wenting Song; Yibo Wen; Jiwei Li; Qingxin Xia; Mingzhi Zhang
Journal:  Front Oncol       Date:  2020-04-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.